Your browser doesn't support javascript.
loading
A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1.
Hai, Ling; Hoffmann, Dirk C; Wagener, Robin J; Azorin, Daniel D; Hausmann, David; Xie, Ruifan; Huppertz, Magnus-Carsten; Hiblot, Julien; Sievers, Philipp; Heuer, Sophie; Ito, Jakob; Cebulla, Gina; Kourtesakis, Alexandros; Kaulen, Leon D; Ratliff, Miriam; Mandelbaum, Henriette; Jung, Erik; Jabali, Ammar; Horschitz, Sandra; Ernst, Kati J; Reibold, Denise; Warnken, Uwe; Venkataramani, Varun; Will, Rainer; Suvà, Mario L; Herold-Mende, Christel; Sahm, Felix; Winkler, Frank; Schlesner, Matthias; Wick, Wolfgang; Kessler, Tobias.
Afiliação
  • Hai L; Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hoffmann DC; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Wagener RJ; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Azorin DD; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Hausmann D; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Xie R; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Huppertz MC; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Hiblot J; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sievers P; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Heuer S; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Ito J; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Cebulla G; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Kourtesakis A; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Kaulen LD; Department of Chemical Biology, Max Planck Institute for Medical Research, Heidelberg, Germany.
  • Ratliff M; Department of Chemical Biology, Max Planck Institute for Medical Research, Heidelberg, Germany.
  • Mandelbaum H; Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Jung E; Clinical Cooperation Unit Neuropathology, DKTK, DKFZ, Heidelberg, Germany.
  • Jabali A; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Horschitz S; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Ernst KJ; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Reibold D; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Warnken U; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Venkataramani V; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Will R; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Suvà ML; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Herold-Mende C; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Sahm F; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Winkler F; Neurosurgery Clinic, University Hospital Mannheim, Mannheim, Germany.
  • Schlesner M; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Wick W; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Kessler T; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Nat Commun ; 15(1): 968, 2024 Feb 06.
Article em En | MEDLINE | ID: mdl-38320988
ABSTRACT
Tumor microtubes (TMs) connect glioma cells to a network with considerable relevance for tumor progression and therapy resistance. However, the determination of TM-interconnectivity in individual tumors is challenging and the impact on patient survival unresolved. Here, we establish a connectivity signature from single-cell RNA-sequenced (scRNA-Seq) xenografted primary glioblastoma (GB) cells using a dye uptake methodology, and validate it with recording of cellular calcium epochs and clinical correlations. Astrocyte-like and mesenchymal-like GB cells have the highest connectivity signature scores in scRNA-sequenced patient-derived xenografts and patient samples. In large GB cohorts, TM-network connectivity correlates with the mesenchymal subtype and dismal patient survival. CHI3L1 gene expression serves as a robust molecular marker of connectivity and functionally influences TM networks. The connectivity signature allows insights into brain tumor biology, provides a proof-of-principle that tumor cell TM-connectivity is relevant for patients' prognosis, and serves as a robust prognostic biomarker.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Glioma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Glioma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article